The usage of systemic enzyme therapy in combination treatment of erysipelas: the assessment by the pharmacoeconomic positions
https://doi.org/10.22625/2072-6732-2014-6-3-79-83
Abstract
Purpose. The aim of the study was to estimate the efficiency and economic feasibility of prescribing systemic enzyme therapy in the composition with standard etiotropic and pathogenetic therapy of erysipelas of lower extremities.
Materials and methods. For this purpose, 62 patients with erysipelas of lower extremities were investigated. Standard therapy (antibiotics, non-steroids, anti-inflammatories) was administered in the 1th group of patients (n=32), patients of the 2th group (n=30) received natural systemic proteolytic enzymes within the acute period of disease additionally to the basic scheme of therapy. The clinic-economic parameters such as cost of illness and the indicator “cost-efficiency” were estimated.
Results. The study has revealed the clinic and economic efficiency of systemic enzyme therapy in the combination therapy of erysipelas, which was confirmed by significant reduction of duration of in-patient treatment and decreasing the rate of recurrence of the disease, reduction of the full cost of the disease and the level of cost-effectivenes.
Conclusion. Use of systemic enzymes is economically feasible and can reduce the full cost of treatment andincrease its efficiency
About the Authors
N. Yu. Pshenichnaya
Rostov State Medical University, Rostov-on-Don, Russia
Russian Federation
Russian Federation
T. V. Moskovaya
Rostov State Medical University, Rostov-on-Don, Russia
Russian Federation
Russian Federation
A. V. Chistyakov
Rostov State Medical University, Rostov-on-Don, Russia
Russian Federation
Russian Federation
A. V. Usatkin
Rostov State Medical University, Rostov-on-Don, Russia
Russian Federation
Russian Federation
References
1. Аmbalov YU. M., Pshenichnaya N.YU., Аkhmidinova M.V. EHpidemiologicheskij analiz zabolevaemosti rozhej v g. Rostove-na-Donu //Uspekhi sovremennogo estestvoznaniya.- Moskva.-2004.-№8-S.62.
2. Pshenichnaya N.YU., Moskovaya T.V., Dobaeva N.M. Klinicheskaya i patogeneticheskaya ehffektivnosti primeneniya preparatov sistemnoj ehnzimoterapii v lechenii rozhi nizhnikh konechnostej.// Fundamental’nye issledovaniya. – 2014. – №4- S. 120-127.
3. Sizyakina L.P. Sistemnaya ehnzimoterapiya pri lechenii allergicheskikh i immunooposredovannykh zabolevanij/ L.P. Sizyakina. – SPb.,2006. – 360s.
4. Hoste E, Kemperman P, Devos M, Denecker G et.all. Caspase-14 is required for filaggrin degradation to natural moisturizing factors in the skin. J Invest Dermatol. 2011 Nov;131(11):2233-41.
5. Miyai M1, Matsumoto Y1, Yamanishi H1, Yamamoto- Tanaka M. Keratinocyte-Specific Mesotrypsin Contributesto Desquamation Process via Kallikrein Activation and LEKTI Degradation. J Invest Dermatol. 2014 Jan 3. doi: 10.1038/jid.2014.3
6. Vorob’ev P.А. Kliniko-ehkonomicheskij analiz/P.А. Vorob’ev – M.; «N’yudiamed», 2008. – 778 s.
7. Ob utverzhdenii otraslevogo standarta «Kliniko-ehkonomicheskie issledovaniya. Obshhie polozheniya»: Prikaz Ministerstva zdravookhraneniya RF №163 ot 27 maya 2002 g. – 13 c.
8. Tkachev А.V. Oslozhnennye formy yazvennoj bolezni: programma lecheniya i reabilitatsii, kliniko-ehkonomicheskij analiz: Diss…d-ra. med. nauk/ А.V. Tkachev. -Rostov-na-Donu, 2001.-395 s.
Review
For citations:
Pshenichnaya N.Yu., Moskovaya T.V., Chistyakov A.V., Usatkin A.V. The usage of systemic enzyme therapy in combination treatment of erysipelas: the assessment by the pharmacoeconomic positions. Journal Infectology. 2014;6(3):79-83. (In Russ.) https://doi.org/10.22625/2072-6732-2014-6-3-79-83
Views:
564
.png)
.png)
Email this article 